ClinicalTrials.gg
CompletedNCT03309826Updated Oct 23, 2023

Positive Airway Pressure Treatment of Obstructive Sleep-disordered Breathing in Hypertensive Disorders of Pregnancy

An interventional study of Positive Airway Pressure and Nasal Dilator Strip in Hypertensive Disorder of Pregnancy and Sleep Apnea, Obstructive, sponsored by Dr John Kimoff. Completed at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Dr John Kimoff · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to conduct a pilot randomized, controlled trial to evaluate the feasibility and obtain pilot outcome data for a subsequent definitive trial evaluating the effects of postitive airway pressure (PAP) treatment of obstructive sleep-disordered breathing (OSDB) on blood pressure control and maternal and fetal outcomes in hypertensive disorders of pregnancy. The primary aim of the pilot study is to assess feasibility measured as the rates of subject recruitment, adequate (>4h/night) PAP adherence (primary outcome measure) and protocol completion. Secondary aims will be to obtain preliminary data on the effects of PAP on maternal blood pressure, complications of hypertension, arterial stiffness and vascular biomarkers, course of labor and delivery and fetal outcomes including growth restriction, prematurity, and neonatal distress.

02

Conditions studied

  • Hypertensive Disorder of Pregnancy
  • Sleep Apnea, Obstructive

Keywords

  • gestational hypertension
  • pre-eclampsia
  • eclampsia
  • obstructive sleep apnea-hypopnea
  • positive airway pressure
  • polysomnography
  • blood pressure
  • arterial stiffness
03

In context

Sleep Apnea, Obstructive

2,240 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

This study's enrollment of 48 is close to the median of 52 across 1,472 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

This is the only study on the registry with Dr John Kimoff as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 y with a singleton pregnancy, ≥ 12 weeks' gestation
  • diagnosis of hypertensive disorder of pregnancy, including pre-existing hypertension, gestational hypertension and pre-eclampsia, as defined by Canadian Hypertensive Disorders of Pregnancy Working Group Criteria (Magee et al; Best Practice and Research Clinical obstetrics \& Gynaecology. 2015;29(5):643-657)
  • presence of obstructive sleep-disordered breathing (OSDB) on a single night in-home complete (Level 2) polysomnogram defined by an apnea-hypopnea index (AHI) ≥ 5 events/h and/or the presence of inspiratory flow limitation on ≥ 30% of breaths.

Exclusion criteria

Exclusion Criteria:

  • severe pre-eclampsia/eclampsia requiring urgent delivery
  • chronic kidney disease or other secondary cause of hypertension
  • known cardiac disease, /stroke
  • or other chronic medical or psychiatric condition
  • smoking, alcohol use, illicit drugs
  • current/recent treatment for sleep-disordered breathing
  • severe sleep-disordered breathing defined as an apnea-hypopnea index (AHI) ≥ 30/h with either severe sleepiness (Epworth sleepiness score ≥ 15) or hypoxemia (4% Oxygen Desaturation Index ≥30/h or arterial oxygen saturation (SpO2) \<80% for >10% of Total Sleep Time)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    PAP Treatment Arm

    Automated positive airway pressure titration then treatment with fixed PAP.

    Device: Positive Airway Pressure

  • Active comparator
    Nasal Dilator Strip

    Nightly use of nasal dilator strip

    Device: Nasal Dilator Strip

Interventions

  • DevicePositive Airway Pressure

    Auto-PAP titration followed by fixed PAP treatment

    Also known as: PAP

  • DeviceNasal Dilator Strip

    Nightly use of nasal dilator strip

06

What researchers measure

Primary outcomes

  1. PAP Adherence

    The proportion of subjects demonstrating \>4h/night CPAP use by objective; microprocessor monitoring

    Time frame: Through study completion, 8 weeks post-partum

Secondary outcomes

  1. Subject recruitment rates

    Percent recruitment of eligible subjects

    Time frame: Through study completion, 8 weeks post-partum

  2. Subject retention rates

    Number of subjects completing the study protocol

    Time frame: Through study completion, 8 weeks post-partum

  3. Maternal 24 hour blood pressure

    24 hour ambulatory blood pressure

    Time frame: Baseline, approximately one week prior to delivery and 8 weeks post-partum

  4. Maternal blood pressure

    Standardized blood pressure measurements using "BPTru" device

    Time frame: Baseline, approximately one week prior to delivery and 8 weeks post-partum

  5. Arterial stiffness measured as carotid-femoral pulse wave velocity

    Non-invasive measurement of arterial stiffness using applanation tonometry

    Time frame: Baseline, approximately one week prior to delivery and 8 weeks post-partum

  6. Epworth Sleepiness Score

    Standard subjective sleepiness score

    Time frame: Baseline, approximately one week prior to delivery and 8 weeks post-partum

  7. Pittsburgh Sleep Quality Index

    Subjective sleep quality index

    Time frame: Baseline, approximately one week prior to delivery and 8 weeks post-partum

  8. Restless leg syndrome questionnaire

    International Restless Legs Study Group questionnaire

    Time frame: Baseline, approximately one week prior to delivery and 8 weeks post-partum

  9. Functional Outcomes of Sleep Questionnaire

    Sleep-related quality of life questionnaire

    Time frame: Baseline, approximately one week prior to delivery and 8 weeks post-partum

07

Study locations

1 site
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03309826
Lead sponsor
Dr John Kimoff
Collaborators
Canadian Institutes of Health Research (CIHR), ResMed Canada Inc.
Responsible party
Dr John Kimoff (Professor of Medicine, McGill University) — Sponsor-investigator
First posted
Oct 16, 2017
Start date
Oct 16, 2017
Primary completion
Jul 30, 2021
Completion
Dec 31, 2021
Last update
Oct 23, 2023

Study contacts

John Kimoff, MD
principal investigator · McGill University Health Centre/Research Institute of the McGill University Health Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion